Helger G. Yntema
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Helger G. Yntema.
Nature | 2014
Christian Gilissen; Jayne Y. Hehir-Kwa; Djie Tjwan Thung; Maartje van de Vorst; Bregje W.M. van Bon; Marjolein H. Willemsen; Michael P. Kwint; Irene M. Janssen; Alexander Hoischen; Annette Schenck; Richard Leach; Robert C. Klein; Rick Tearle; Tan Bo; Rolph Pfundt; Helger G. Yntema; Bert B.A. de Vries; Tjitske Kleefstra; Han G. Brunner; Lisenka E.L.M. Vissers; Joris A. Veltman
Severe intellectual disability (ID) occurs in 0.5% of newborns and is thought to be largely genetic in origin. The extensive genetic heterogeneity of this disorder requires a genome-wide detection of all types of genetic variation. Microarray studies and, more recently, exome sequencing have demonstrated the importance of de novo copy number variations (CNVs) and single-nucleotide variations (SNVs) in ID, but the majority of cases remain undiagnosed. Here we applied whole-genome sequencing to 50 patients with severe ID and their unaffected parents. All patients included had not received a molecular diagnosis after extensive genetic prescreening, including microarray-based CNV studies and exome sequencing. Notwithstanding this prescreening, 84 de novo SNVs affecting the coding region were identified, which showed a statistically significant enrichment of loss-of-function mutations as well as an enrichment for genes previously implicated in ID-related disorders. In addition, we identified eight de novo CNVs, including single-exon and intra-exonic deletions, as well as interchromosomal duplications. These CNVs affected known ID genes more frequently than expected. On the basis of diagnostic interpretation of all de novo variants, a conclusive genetic diagnosis was reached in 20 patients. Together with one compound heterozygous CNV causing disease in a recessive mode, this results in a diagnostic yield of 42% in this extensively studied cohort, and 62% as a cumulative estimate in an unselected cohort. These results suggest that de novo SNVs and CNVs affecting the coding region are a major cause of severe ID. Genome sequencing can be applied as a single genetic test to reliably identify and characterize the comprehensive spectrum of genetic variation, providing a genetic diagnosis in the majority of patients with severe ID.
Human Mutation | 2013
Kornelia Neveling; Ilse Feenstra; Christian Gilissen; Lies H. Hoefsloot; Erik-Jan Kamsteeg; Arjen R. Mensenkamp; Richard J. Rodenburg; Helger G. Yntema; Liesbeth Spruijt; Sascha Vermeer; Tuula Rinne; Koen L. van Gassen; Danielle Bodmer; Dorien Lugtenberg; Rick de Reuver; Wendy Buijsman; Ronny Derks; Nienke Wieskamp; Bert van den Heuvel; Marjolijn J. L. Ligtenberg; Hannie Kremer; David A. Koolen; Bart P. van de Warrenburg; Frans P.M. Cremers; Carlo Marcelis; Jan A.M. Smeitink; Saskia B. Wortmann; Wendy A. G. van Zelst-Stams; Joris A. Veltman; Han G. Brunner
The advent of massive parallel sequencing is rapidly changing the strategies employed for the genetic diagnosis and research of rare diseases that involve a large number of genes. So far it is not clear whether these approaches perform significantly better than conventional single gene testing as requested by clinicians. The current yield of this traditional diagnostic approach depends on a complex of factors that include gene‐specific phenotype traits, and the relative frequency of the involvement of specific genes. To gauge the impact of the paradigm shift that is occurring in molecular diagnostics, we assessed traditional Sanger‐based sequencing (in 2011) and exome sequencing followed by targeted bioinformatics analysis (in 2012) for five different conditions that are highly heterogeneous, and for which our center provides molecular diagnosis. We find that exome sequencing has a much higher diagnostic yield than Sanger sequencing for deafness, blindness, mitochondrial disease, and movement disorders. For microsatellite‐stable colorectal cancer, this was low under both strategies. Even if all genes that could have been ordered by physicians had been tested, the larger number of genes captured by the exome would still have led to a clearly superior diagnostic yield at a fraction of the cost.
American Journal of Human Genetics | 2004
Efraim H. Rosenberg; Lígia S. Almeida; Tjitske Kleefstra; Rose S. deGrauw; Helger G. Yntema; Nadia Bahi; Claude Moraine; Hans-Hilger Ropers; Jean-Pierre Fryns; Ton J. deGrauw; Cornelis Jakobs; Gajja S. Salomons
A novel X-linked mental retardation (XLMR) syndrome was recently identified, resulting from creatine deficiency in the brain caused by mutations in the creatine transporter gene, SLC6A8. We have studied the prevalence of SLC6A8 mutations in a panel of 290 patients with nonsyndromic XLMR archived by the European XLMR Consortium. The full-length open reading frame and splice sites of the SLC6A8 gene were investigated by DNA sequence analysis. Six pathogenic mutations, of which five were novel, were identified in a total of 288 patients with XLMR, showing a prevalence of at least 2.1% (6/288). The novel pathogenic mutations are a nonsense mutation (p.Y317X) and four missense mutations. Three missense mutations (p.G87R, p.P390L, and p.P554L) were concluded to be pathogenic on the basis of conservation, segregation, chemical properties of the residues involved, as well as the absence of these and any other missense mutation in 276 controls. For the p.C337W mutation, additional material was available to biochemically prove (i.e., by increased urinary creatine : creatinine ratio) pathogenicity. In addition, we found nine novel polymorphisms (IVS1+26G-->A, IVS7+37G-->A, IVS7+87A-->G, IVS7-35G-->A, IVS12-3C-->T, IVS2+88G-->C, IVS9-36G-->A, IVS12-82G-->C, and p.Y498) that were present in the XLMR panel and/or in the control panel. Two missense variants (p.V629I and p.M560V) that were not highly conserved and were not associated with increased creatine : creatinine ratio, one translational silent variant (p.L472), and 10 intervening sequence variants or untranslated region variants (IVS6+9C-->T, IVS7-151_152delGA, IVS7-99C-->A, IVS8-35G-->A, IVS8+28C-->T, IVS10-18C-->T, IVS11+21G-->A, IVS12+15C-->T, *207G-->C, IVS12+32C-->A) were found only in the XLMR panel but should be considered as unclassified variants or as a polymorphism (p.M560V). Our data indicate that the frequency of SLC6A8 mutations in the XLMR population is close to that of CGG expansions in FMR1, the gene responsible for fragile-X syndrome.
American Journal of Human Genetics | 2010
Simone Martinelli; Alessandro De Luca; Emilia Stellacci; Cesare Rossi; Saula Checquolo; Francesca Lepri; Viviana Caputo; Marianna Silvano; Francesco Buscherini; Federica Consoli; Grazia Ferrara; Maria Cristina Digilio; Maria Luigia Cavaliere; Johanna M. van Hagen; Giuseppe Zampino; Ineke van der Burgt; Giovanni Battista Ferrero; Laura Mazzanti; Isabella Screpanti; Helger G. Yntema; Willy M. Nillesen; Ravi Savarirayan; Martin Zenker; Bruno Dallapiccola; Bruce D. Gelb; Marco Tartaglia
RAS signaling plays a key role in controlling appropriate cell responses to extracellular stimuli and participates in early and late developmental processes. Although enhanced flow through this pathway has been established as a major contributor to oncogenesis, recent discoveries have revealed that aberrant RAS activation causes a group of clinically related developmental disorders characterized by facial dysmorphism, a wide spectrum of cardiac disease, reduced growth, variable cognitive deficits, ectodermal and musculoskeletal anomalies, and increased risk for certain malignancies. Here, we report that heterozygous germline mutations in CBL, a tumor-suppressor gene that is mutated in myeloid malignancies and encodes a multivalent adaptor protein with E3 ubiquitin ligase activity, can underlie a phenotype with clinical features fitting or partially overlapping Noonan syndrome (NS), the most common condition of this disease family. Independent CBL mutations were identified in two sporadic cases and two families from among 365 unrelated subjects who had NS or suggestive features and were negative for mutations in previously identified disease genes. Phenotypic heterogeneity and variable expressivity were documented. Mutations were missense changes altering evolutionarily conserved residues located in the RING finger domain or the linker connecting this domain to the N-terminal tyrosine kinase binding domain, a known mutational hot spot in myeloid malignancies. Mutations were shown to affect CBL-mediated receptor ubiquitylation and dysregulate signal flow through RAS. These findings document that germline mutations in CBL alter development to cause a clinically variable condition that resembles NS and that possibly predisposes to malignancies.
Journal of Medical Genetics | 2009
Tjitske Kleefstra; W.A.G. van Zelst-Stams; Willy M. Nillesen; Valérie Cormier-Daire; Gunnar Houge; Nicola Foulds; M.F. van Dooren; Marjolein H. Willemsen; Rolph Pfundt; Anne Turner; Meredith Wilson; Julie McGaughran; Anita Rauch; Martin Zenker; Margaret P Adam; M Innes; C Davies; A González-Meneses López; R Casalone; A Weber; Louise Brueton; A Delicado Navarro; M Palomares Bralo; Hanka Venselaar; S P A Stegmann; Helger G. Yntema; H. van Bokhoven; Han G. Brunner
Background: The 9q subtelomeric deletion syndrome (9qSTDS) is clinically characterised by moderate to severe mental retardation, childhood hypotonia and facial dysmorphisms. In addition, congenital heart defects, urogenital defects, epilepsy and behavioural problems are frequently observed. The syndrome can be either caused by a submicroscopic 9q34.3 deletion or by intragenic EHMT1 mutations leading to haploinsufficiency of the EHMT1 gene. So far it has not been established if and to what extent other genes in the 9q34.3 region contribute to the phenotype observed in deletion cases. This study reports the largest cohort of 9qSTDS cases so far. Methods and results: By a multiplex ligation dependent probe amplification (MLPA) approach, the authors identified and characterised 16 novel submicroscopic 9q deletions. Direct sequence analysis of the EHMT1 gene in 24 patients exhibiting the 9qSTD phenotype without such deletion identified six patients with an intragenic EHMT1 mutation. Five of these mutations predict a premature termination codon whereas one mutation gives rise to an amino acid substitution in a conserved domain of the protein. Conclusions: The data do not provide any evidence for phenotype–genotype correlations between size of the deletions or type of mutations and severity of clinical features. Therefore, the authors confirm the EHMT1 gene to be the major determinant of the 9qSTDS phenotype. Interestingly, five of six patients who had reached adulthood had developed severe psychiatric pathology, which may indicate that EHMT1 haploinsufficiency is associated with neurodegeneration in addition to neurodevelopmental defect.
European Journal of Human Genetics | 2016
Gert Matthijs; Erika Souche; Marielle Alders; Anniek Corveleyn; Sebastian Eck; Ilse Feenstra; Valerie Race; Erik A. Sistermans; Marc Sturm; Marjan M. Weiss; Helger G. Yntema; Egbert Bakker; Hans Scheffer; Peter Bauer
We present, on behalf of EuroGentest and the European Society of Human Genetics, guidelines for the evaluation and validation of next-generation sequencing (NGS) applications for the diagnosis of genetic disorders. The work was performed by a group of laboratory geneticists and bioinformaticians, and discussed with clinical geneticists, industry and patients’ representatives, and other stakeholders in the field of human genetics. The statements that were written during the elaboration of the guidelines are presented here. The background document and full guidelines are available as supplementary material. They include many examples to assist the laboratories in the implementation of NGS and accreditation of this service. The work and ideas presented by others in guidelines that have emerged elsewhere in the course of the past few years were also considered and are acknowledged in the full text. Interestingly, a few new insights that have not been cited before have emerged during the preparation of the guidelines. The most important new feature is the presentation of a ‘rating system’ for NGS-based diagnostic tests. The guidelines and statements have been applauded by the genetic diagnostic community, and thus seem to be valuable for the harmonization and quality assurance of NGS diagnostics in Europe.
Journal of Medical Genetics | 2005
Tjitske Kleefstra; M. Smidt; Martijn J.G. Banning; Astrid R. Oudakker; H. Van Esch; A.P.M. de Brouwer; Willy M. Nillesen; Erik A. Sistermans; B.C.J. Hamel; D.R.H. de Bruijn; J. P. Fryns; Helger G. Yntema; Han G. Brunner; L.B.A. de Vries; J.H.L.M. van Bokhoven
Background: A new syndrome has been recognised following thorough analysis of patients with a terminal submicroscopic subtelomeric deletion of chromosome 9q. These have in common severe mental retardation, hypotonia, brachycephaly, flat face with hypertelorism, synophrys, anteverted nares, thickened lower lip, carp mouth with macroglossia, and conotruncal heart defects. The minimum critical region responsible for this 9q subtelomeric deletion syndrome (9q−) is approximately 1.2 Mb and encompasses at least 14 genes. Objective: To characterise the breakpoints of a de novo balanced translocation t(X;9)(p11.23;q34.3) in a mentally retarded female patient with clinical features similar to the 9q− syndrome. Results: Sequence analysis of the break points showed that the translocation was fully balanced and only one gene on chromosome 9 was disrupted—Euchromatin Histone Methyl Transferase1 (Eu-HMTase1)—encoding a histone H3 lysine 9 methyltransferase (H3-K9 HMTase). This indicates that haploinsufficiency of Eu-HMTase1 is responsible for the 9q submicroscopic subtelomeric deletion syndrome. This observation was further supported by the spatio-temporal expression of the gene. Using tissue in situ hybridisation studies in mouse embryos and adult brain, Eu-HMTase1 was shown to be expressed in the developing nervous system and in specific peripheral tissues. While expression is selectively downregulated in adult brain, substantial expression is retained in the olfactory bulb, anterior/ventral lateral ventricular wall, and hippocampus and weakly in the piriform cortex. Conclusions: The expression pattern of this gene suggests a role in the CNS development and function, which is in line with the severe mental retardation and behaviour problems in patients who lack one copy of the gene.
Nature Genetics | 2003
Vera M. Kalscheuer; Kristine Freude; Luciana Musante; Lars R. Jensen; Helger G. Yntema; Jozef Gecz; Abdelaziz Sefiani; Kirsten Hoffmann; Bettina Moser; Stefan A. Haas; Ulf Gurok; Sebastian Haesler; Beatriz Aranda; Arpik Nshedjan; Andreas Tzschach; Nils Hartmann; Tim-Christoph Roloff; Sarah A. Shoichet; Olivier Hagens; Jiong Tao; Hans van Bokhoven; Gillian Turner; Jamel Chelly; Claude Moraine; Jean-Pierre Fryns; Ulrike A. Nuber; Maria Hoeltzenbein; Constance Scharff; Harry Scherthan; Steffen Lenzner
We found mutations in the gene PQBP1 in 5 of 29 families with nonsyndromic (MRX) and syndromic (MRXS) forms of X-linked mental retardation (XLMR). Clinical features in affected males include mental retardation, microcephaly, short stature, spastic paraplegia and midline defects. PQBP1 has previously been implicated in the pathogenesis of polyglutamine expansion diseases. Our findings link this gene to XLMR and shed more light on the pathogenesis of this common disorder.
Nature Genetics | 2014
Céline Helsmoortel; Anneke T. Vulto-van Silfhout; Bradley P. Coe; Geert Vandeweyer; Liesbeth Rooms; Jenneke van den Ende; Janneke H M Schuurs-Hoeijmakers; Carlo Marcelis; Marjolein H. Willemsen; Lisenka E.L.M. Vissers; Helger G. Yntema; Madhura Bakshi; Meredith Wilson; Kali Witherspoon; Helena Malmgren; Ann Nordgren; Göran Annerén; Marco Fichera; Paolo Bosco; Corrado Romano; Bert B.A. de Vries; Tjitske Kleefstra; R. Frank Kooy; Evan E. Eichler; Nathalie Van der Aa
Despite the high heritability of autism spectrum disorders (ASD), characterized by persistent deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests or activities, a genetic diagnosis can be established in only a minority of patients. Known genetic causes include chromosomal aberrations, such as the duplication of the 15q11-13 region, and monogenic causes, as in Rett and fragile-X syndromes. The genetic heterogeneity within ASD is striking, with even the most frequent causes responsible for only 1% of cases at the most. Even with the recent developments in next-generation sequencing, for the large majority of cases no molecular diagnosis can be established. Here, we report ten patients with ASD and other shared clinical characteristics, including intellectual disability and facial dysmorphisms caused by a mutation in ADNP, a transcription factor involved in the SWI/SNF remodeling complex. We estimate this gene to be mutated in at least 0.17% of ASD cases, making it one of the most frequent ASD-associated genes known to date.
Nature Genetics | 2012
David A. Koolen; Jamie M. Kramer; Kornelia Neveling; Willy M. Nillesen; Heather L. Moore-Barton; Frances Elmslie; Annick Toutain; Jeanne Amiel; Valérie Malan; Anne Chun Hui Tsai; Sau Wai Cheung; Christian Gilissen; Eugène T P Verwiel; Sarah Martens; Ton Feuth; Ernie M.H.F. Bongers; Petra de Vries; H. Scheffer; Lisenka E.L.M. Vissers; Arjan P.M. de Brouwer; Han G. Brunner; Joris A. Veltman; Annette Schenck; Helger G. Yntema; Bert B.A. de Vries
We show that haploinsufficiency of KANSL1 is sufficient to cause the 17q21.31 microdeletion syndrome, a multisystem disorder characterized by intellectual disability, hypotonia and distinctive facial features. The KANSL1 protein is an evolutionarily conserved regulator of the chromatin modifier KAT8, which influences gene expression through histone H4 lysine 16 (H4K16) acetylation. RNA sequencing studies in cell lines derived from affected individuals and the presence of learning deficits in Drosophila melanogaster mutants suggest a role for KANSL1 in neuronal processes.